Mckay Alexander, Burgio Gaetan
Department of Immunology and Infectious Diseases, John Curtin School of Medical Research, Australian National University, Canberra, ACT 2601, Australia.
J Biomed Res. 2021 Mar 26;35(2):91-106. doi: 10.7555/JBR.35.20200184.
The discovery and utilization of RNA-guided surveillance complexes, such as CRISPR-Cas9, for sequence-specific DNA or RNA cleavage, has revolutionised the process of gene modification or knockdown. To optimise the use of this technology, an exploratory race has ensued to discover or develop new RNA-guided endonucleases with the most flexible sequence targeting requirements, coupled with high cleavage efficacy and specificity. Here we review the constraints of existing gene editing and assess the merits of exploiting the diversity of CRISPR-Cas effectors as a methodology for surmounting these limitations.
RNA引导的监测复合物(如CRISPR-Cas9)用于序列特异性DNA或RNA切割的发现与应用,彻底改变了基因修饰或敲低的过程。为了优化这项技术的使用,一场探索竞赛随之展开,旨在发现或开发具有最灵活序列靶向要求、同时具备高切割效率和特异性的新型RNA引导的核酸内切酶。在此,我们回顾现有基因编辑的局限性,并评估利用CRISPR-Cas效应物的多样性作为克服这些限制的一种方法的优点。